Article
Medicine, Research & Experimental
Florian Rosar, Fabian Hau, Mark Bartholoma, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Samer Ezziddin, Fadi Khreish
Summary: The study found that [Ac-225]Ac-PSMA-617/[Lu-177]Lu-PSMA-617 tandem therapy is effective for mCRPC patients who have progressed on [Lu-177]Lu-PSMA-617 monotherapy. Molecular imaging response and biochemical PSA response were mostly concordant, although there were a considerable number of discordant cases.
Article
Radiology, Nuclear Medicine & Medical Imaging
Shahneen Sandhu, Christina Guo, Michael S. Hofman
Summary: Despite advances in therapeutic developments for prostate cancer, metastatic prostate cancer remains lethal. PSMA is an important target for theranostic approaches in this disease, but resistance and limited therapeutic window remain challenges. Understanding PSMA biology, pharmacokinetics and pharmacodynamics of PSMA-targeted RNT, and mechanisms of resistance may improve efficacy and safety of treatments.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Ying Chen, Il Minn, Steven P. Rowe, Alla Lisok, Samit Chatterjee, Mary Brummet, Sangeeta Ray Banerjee, Ronnie C. Mease, Martin G. Pomper
Summary: We have synthesized a series of near-infrared imaging agents targeting PSMA for use in fluorescence-guided surgery. The compounds were designed to improve pharmacokinetics by altering the linker between the PSMA-targeting urea moiety and the fluorophore. These compounds show potential for FGS in prostate, renal or other PSMA-expressing cancers.
Review
Oncology
Seiji Hoshi, Kei Yaginuma, Satoru Meguro, Akifumi Onagi, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Motohide Uemura, Yoshiyuki Kojima
Summary: Theranostics using PSMA ligands is a promising therapy for prostate cancer, but its efficacy depends on PSMA expression and other predictors of treatment response. The optimal patient population for PSMA-RLT is still unclear.
Article
Radiology, Nuclear Medicine & Medical Imaging
Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A. Hoffmann, Mathias Schreckenberger, Mark Bartholoma, Samer Ezziddin
Summary: In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), early change of total lesion PSMA (TLP) on molecular imaging independently predicts overall survival, outperforming conventional PSA-based response assessment. Total lesion PSMA (TLP) may be considered as a more advanced biomarker for monitoring PSMA-RLT compared to serum PSA.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bastiaan M. Prive, Yvonne H. W. Derks, Florian Rosar, Gerben M. Franssen, Steffie M. B. Peters, Fadi Khreish, Mark Bartholomae, Stephan Maus, Martin Gotthardt, Peter Laverman, Mark W. Konijnenberg, Samer Ezziddin, James Nagarajah, Sandra Heskamp
Summary: This study successfully labeled PSMA-617 and PSMA-I&T with Zr-89, demonstrating high uptake in PSMA(+) xenografts for PET imaging up to 168 hours post-injection. The biodistribution of Zr-89-PSMA-I&T and Zr-89-PSMA-617 resembled that of Lu-177-PSMA-I&T and Lu-177-PSMA-617, respectively. The first patient Zr-89-PSMA-617 PET images showed high quality, warranting further clinical investigation.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Multidisciplinary Sciences
Yu Wang, Al Christopher De Leon, Reshani Perera, Eric Abenojar, Ramamurthy Gopalakrishnan, James P. Basilion, Xinning Wang, Agata A. Exner
Summary: Ultrasound imaging is commonly used for guiding prostate biopsies, but accurately delineating tumors within the prostate gland remains challenging. This study evaluated a novel nanobubble ultrasound contrast agent targeted to PSMA, showing increased extravasation and retention in PSMA-expressing mouse tumors, potentially improving image-based detection and diagnosis of PCa in the future.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Mohammed Abusalem, Lucia Martiniova, Sarita Soebianto, Louis Depalatis, Gregory Ravizzini
Summary: PSMA is a promising molecular target in prostate cancer, and monoclonal antibodies (mAbs) have been widely used for targeting cancer cells with high specificity and minimal side effects. Radioactive mAbs conjugates can be used for imaging and treatment. This article provides an overview of the current development and future prospects of radioactive mAbs conjugates targeting PSMA in prostate cancer.
Review
Biochemistry & Molecular Biology
Sashi Debnath, Ning Zhou, Mark McLaughlin, Samuel Rice, Anil K. Pillai, Guiyang Hao, Xiankai Sun
Summary: In recent years, significant progress has been made in PSMA-targeted imaging and therapeutic agents for prostate cancer, focusing on improving pharmacokinetics and enhancing specific binding affinity to increase detection sensitivity and specificity, while minimizing toxicity to non-target tissues.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Hao Li, Dong Luo, Chaonan Yuan, Xinning Wang, Jing Wang, James P. Basilion, Thomas J. Meade
Summary: PSMA is a transmembrane protein highly expressed in aggressive prostate cancer, utilized in various imaging modalities as a biomarker. MR imaging provides detailed information but requires development of molecular contrast agents for improved sensitivity. In this study, targeted and activatable MR contrast agents were successfully used to differentiate between PSMA+ and PSMA- prostate cancer cells.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2021)
Article
Engineering, Biomedical
Qiang Liu, Jiangwei Tian, Ye Tian, Qinchao Sun, Dan Sun, Dewen Liu, Feifei Wang, Haijun Xu, Guoliang Ying, Jigang Wang, Ali K. Yetisen, Nan Jiang
Summary: Organic fluorophores/photosensitizers have limited applications in the second near-infrared (NIR-II) window due to low fluorescence quantum yields. A boron dipyrromethene (BDP) with high QYs and thiophene donor unit is created for single NIR laser-triggered phototherapeutic nanoparticles. These NPs exhibit high solubility, singlet oxygen QY, multifunctional characteristics, and high signal-to-background ratio in tumor-bearing mice.
ACTA BIOMATERIALIA
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrea Farolfi, Letizia Calderoni, Francesco Mattana, Riccardo Mei, Sivi Telo, Stefano Fanti, Paolo Castellucci
Summary: PSMA PET shows superior detection capabilities for prostate cancer in both primary and recurrent settings, with significant impact on clinical management. It may also play a crucial role in localization and treatment of PCa patients.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Thomas S. C. Ng, Xin Gao, Keyan Salari, Dimitar V. Zlatev, Pedram Heidari, Sophia C. Kamran
Summary: Recent developments in PSMA-targeted theranostics offer promising advancements in the management of primary, recurrent, and metastatic prostate cancer. Coordination among clinical stakeholders from various specialties is essential for maximizing the clinical impact of PSMA-targeted theranostics in prostate cancer management. The current and forthcoming PSMA-based imaging and therapeutics hold great potential in improving prostate cancer management across different stages of the disease.
FRONTIERS IN ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Qiaomiao Lu, Yu Long, Yongkang Gai, Qingyao Liu, Dawei Jiang, Xiaoli Lan
Summary: This study aimed to explore the feasibility of using [Lu-177]Lu-PSMA-617 and [Lu-177]Lu-EB-PSMA-617 for in vivo radioligand therapy in PSMA-positive hepatocellular carcinoma. The results showed that these radioligands significantly suppressed tumor growth and prolonged survival time without obvious toxicity, indicating their potential for clinical use in humans.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Biochemistry & Molecular Biology
Eline A. M. Ruigrok, Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden, Julie Nonnekens
Summary: Combining PSMA-TRT with PARPi did not show synergistic effects on in vitro cell survival or viability in prostate cancer. Only the combination of PSMA-TRT with veliparib resulted in a significant increase in DNA breaks. Furthermore, the combination of PSMA-TRT with PARPi did not improve tumor control compared to PSMA-TRT monotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)